NA
AKTX

NewEdge Advisors’s Akari Therapeutics AKTX Stock Holding History

NewEdge Advisors’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-170
Closed -$1.97K – 4130
2025
Q4 		$1.97K Hold
170
– – ﹤0.01% 3892
2025
Q3 		$6.87K Hold
170
– – ﹤0.01% 3436
2025
Q2 		$7.96K Buy
+170
New +$8.57K ﹤0.01% 3274

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

NewEdge Advisors's AKTX Position: Q1 2026 in Review

NewEdge Advisors sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 170 shares — an estimated $1.97K sold.

NewEdge Advisors first reported a position in AKTX in Q2 2025 and held it in 3 quarters. The position peaked at $7.96K in Q2 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • NewEdge Advisors reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NewEdge Advisors sold 170 Akari Therapeutics shares in Q1 2026, an estimated $1.97K.
  • NewEdge Advisors first reported a position in Akari Therapeutics in Q2 2025 and held it in 3 quarters.
  • NewEdge Advisors's Akari Therapeutics position peaked at $7.96K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.